10x Genomics stock suffering record drop toward record low after revenue warnings prompts downgrade

43303 10x genomics stock suffering record drop toward record low after revenue warnings prompts downgrade

Shares of 10x Genomics Inc. TGX, -4.32% plunged 22.3% in active morning trading Friday, putting them on track to suffer a record one-day drop to a record low Friday, after the biotechnology company’s revenue warning prompted BofA Securities analyst Derik de Bruin to turn bearish. Trading volume was 3.9 million shares, already about triple the full-day average of about 1.3 million shares. 10x’s rating was cut by de Bruin to underperform from neutral, and the stock price target was slashed to $35 from $80. “We are still positive on [10x’s] technology, but he issues will take time to fix and a premium valuation is not justified,” de Bruin wrote in a note to clients. The stock’s previous record one-day decline was 21.0% on May 6, 2021, and the previous record low close was $36.95 on June 13. The stock has plummeted 77.4% year to date, while the iShares Biotechnology ETF IBB, +1.47% has dropped 20.1% and the S&P 500 SPX, +1.92% has slumped 19.1%.

Source: Marketwatch

Related Posts